BioCentury
ARTICLE | Company News

Intercept partners TGR5 program with Servier

August 10, 2011 12:08 AM UTC

Intercept Pharmaceuticals Inc. (New York, N.Y.) partnered with Servier (Neuilly-sur-Seine, France) to discover and develop treatments for Type II diabetes and other metabolic diseases from Intercept's G protein-coupled bile acid receptor 1 ( GPBAR1; TGR5) agonist program. The partners will use Intercept's drug discovery technology, which is based on bile acid analog chemistry. Servier will have rights to the products outside of the U.S. and Japan, where Intercept retains rights. ...